<DOC>
	<DOCNO>NCT01892436</DOCNO>
	<brief_summary>This study design 3-year extension phase III core study CAIN457F2306 . It aim provide continuous treatment secukinumab pre-filled syrinx ( PFS ) subject complete core study CAIN457F2306 , obtain long term efficacy , safety tolerability information subject active psoriatic arthritis receive secukinumab every 4 week . At Week 104 study CAIN457F2306 , eligible subject complete assessment associate core study visit subsequently continue extension study dose receive core study . The regular assessment disease activity ensure subject experience worsen disease treatment group exit study upon wish base advice investigator time .</brief_summary>
	<brief_title>Extension Study 3 Years Secukinumab Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Subjects must able understand communicate investigator comply requirement study must give write , sign date informed consent study assessment perform Subjects must participate core study CAIN457F2306 , must complete entire treatment period Subjects must deem investigator benefit continue secukinumab therapy Exclusion criterion Any subject take concomitant biologic immunomodulating agent ( ) except secukinumab Any subject deem benefit study treatment base upon lack improvement worsen symptom Pregnant nursing ( lactate ) woman Women childbearing potential , unless use effective method contraception entire study longer require locally approve prescribe information ( e.g. , 20 week EU ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Extension study , psoriatic arthritis , pre-filled syringe</keyword>
</DOC>